文献速递甲状腺疾病性腺与生殖内分泌

MCT8基因突变所致甲状腺激素细胞膜转运缺陷的产前治疗

Prenatal Treatment of Thyroid Hormone Cell Membrane Transport Defect Caused by MCT8 Gene Mutation.
PubMed 文献 · Thyroid · 2020-09-25

本文报告一例MCT8基因突变所致甲状腺激素细胞膜转运缺陷的产前治疗:患病男性胎儿的母亲为携带者,自妊娠18周至35周分娩每周羊膜腔内注射左甲状腺素500 μg。出生时患儿血清T4为14.5 μg/dL、TSH<0.01 mU/L,6月龄MRI显示脑髓鞘化接近正常,31月龄发育商12–25,均优于未治疗的患病哥哥。结论认为这是产前治疗改善MCT8缺陷神经运动与神经认知功能的首次展示。

要点

  • MCT8突变致脑内甲状腺激素缺乏、外周T3升高,表现为严重精神神经运动异常和高代谢。
  • 患病胎儿自妊娠18周起每周羊膜腔内注射左甲状腺素500 μg,羊水T4、T3升高而母血清水平不变。
  • 出生时患儿T4为14.5 μg/dL、TSH<0.01 mU/L,6月龄脑髓鞘化接近正常,31月龄发育商12–25。

核心结论

  • 这是产前治疗改善MCT8缺陷神经运动与神经认知功能的首次展示。
  • 作者认为,更早给予能在胎儿体内浓集的甲状腺激素类似物可能进一步挽救表型。

研究设计与样本

  • 病例报告:一名携带MCT8 A252fs268*突变的女性,其患病男性胎儿自妊娠18周至35周分娩接受每周羊膜腔内注射左甲状腺素500 μg。
  • 出生后继续左甲状腺素和丙硫氧嘧啶治疗,随访包括脑MRI和神经发育评估,并与未治疗的患病哥哥比较。

主要发现

  • 宫内治疗期间羊水T4和T3维持在基线三倍至两倍以上,TSH被抑制80%,母血清水平不变。
  • 出生时患儿血清T4为14.5 μg/dL、TSH<0.01 mU/L,未治疗MCT8缺陷婴儿平均分别为5.1 μg/dL和>8 mU/L。
  • 6月龄MRI显示脑髓鞘化接近正常,未治疗哥哥则明显减低。
  • 神经发育评估:接受治疗男孩31月龄时接受性语言、解决问题、粗大运动和精细运动发育商为12–25,未治疗哥哥58月龄时为1–7。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Mutations of the thyroid hormone (TH)-specific cell membrane transporter, monocarboxylate transporter 8 (MCT8), produce an X-chromosome-linked syndrome of TH deficiency in the brain and excess in peripheral tissues. The clinical consequences include brain hypothyroidism causing severe psychoneuromotor abnormalities (no speech, truncal hypotonia, and spastic quadriplegia) and hypermetabolism (poor weight gain, tachycardia, and increased metabolism, associated with high serum levels of the active TH, T3). Treatment in infancy and childhood with TH analogues that reduce serum triiodothyronine (T3) corrects hypermetabolism, but has no effect on the psychoneuromotor deficits. Studies of brain from a 30-week-old MCT8-deficient embryo indicated that brain abnormalities were already present during fetal life. Methods: A carrier woman with an affected male child (MCT8 A252fs268*), pregnant with a second affected male embryo, elected to carry the pregnancy to term. We treated the fetus with weekly 500 μg intra-amniotic instillation of levothyroxine (LT4) from 18 weeks of gestation until birth at 35 weeks. Thyroxine (T4), T3, and thyrotropin (TSH) were measured in the amniotic fluid and maternal serum. Treatment after birth was continued with LT4 and propylthiouracil. Follow-up included brain magnetic resonance imaging (MRI) and neurodevelopmental evaluation, both compared with the untreated brother. Results: During intrauterine life, T4 and T3 in the amniotic fluid were maintained above threefold to twofold the baseline and TSH was suppressed by 80%, while maternal serum levels remained unchanged. At birth, the infant serum T4 was 14.5 μg/dL and TSH <0.01 mU/L compared with the average in untreated MCT8-deficient infants of 5.1 μg/ and >8 mU/L, respectively. MRI at six months of age showed near-normal brain myelination compared with much reduced in the untreated brother. Neurodevelopmental assessment showed developmental quotients in receptive language and problem-solving, and gross motor and fine motor function ranged from 12 to 25 at 31 months in the treated boy and from 1 to 7 at 58 months in the untreated brother. Conclusions: This is the first demonstration that prenatal treatment improved the neuromotor and neurocognitive function in MCT8 deficiency. Earlier treatment with TH analogues that concentrate in the fetus when given to the mother may further rescue the phenotype.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Refetoff S, Pappa T, Williams MK, et al. Prenatal Treatment of Thyroid Hormone Cell Membrane Transport Defect Caused by MCT8 Gene Mutation. Thyroid. 2020. PMID: 32746752. doi:10.1089/thy.2020.0306

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。